TG’s Follicular Lymphoma Data Suggest Umbralisib Could Succeed In PI3K Delta Class
Overall survival data from a follicular lymphoma cohort of its umbrella NHL study indicate umbralisib could match other PI3K delta inhibitors’ efficacy with better safety/tolerability profile.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
Pfizer has received approval from the US Food and Drug Administration for the country’s second biosimilar rituximab, under the Ruxience label. However, the company has not yet revealed launch plans for the rival to Roche’s Rituxan brand.